Brown fat activates uncoupled respiration in response to cold temperature and contributes to systemic metabolic homeostasis. To date, the metabolic action of brown fat has been primarily attributed to its role in fuel oxidation and uncoupling protein 1 (UCP1)-mediated thermogenesis. Whether brown fat engages other tissues through secreted factors remains largely unexplored.
Brown adipose tissue (BAT) defends against excess cold stimulation through its upregulation of mitochondrial UCP1, which links fuel oxidation to heat generation 1, 2 , while also playing an important role in whole-body energy balance and fuel metabolism. Genetic ablation of BAT via transgenic expression of diphtheria toxin A renders mice prone to the development of obesity 3 , whereas activation of BAT thermogenesis by cold exposure has been linked to increased energy expenditure, reduced adiposity and lower plasma lipids [4] [5] [6] . Recent work has demonstrated that metabolically active BAT is present in adult humans [7] [8] [9] [10] , raising the prospect that augmenting brown fat abundance and/or function may provide an effective avenue for the treatment of obesity and its associated metabolic disorders 11, 12 . Although BAT in humans shares key molecular and metabolic characteristics with the classical rodent BAT, it appears to contain both classical and brown-like (beige/brite) 13, 14 adipocytes with distinct molecular signatures and developmental origins [15] [16] [17] .
Brown adipocytes actively take up glucose and fatty acids for oxidation by mitochondria, and the rate of fuel utilization is increased under thermogenic conditions. Surprisingly, while mice lacking UCP1 had heightened sensitivity to cold 18 , they were resistant to diet-induced obesity at ambient temperatures and became more prone to weight gain only at thermoneutrality 19, 20 . The latter is in stark contrast to the obesity-prone phenotype in mice that lack brown fat as a result of genetic ablation 3 . These paradoxical findings strongly suggest that brown fat exerts effects on systemic nutrient and energy metabolism beyond its intrinsic ability to carry out uncoupled respiration. We postulated that brown fat may release factors that act non-cell-autonomously on other tissues to modulate systemic energy metabolism.
Secreted factors are important in mediating metabolic cross-talk among tissues to maintain systemic nutrient and energy homeostasis. Adipose tissue hormones [21] [22] [23] , gut-derived fibroblast growth factors 24, 25 , myokines 26, 27 and bone-derived factors 28 participate in nutrient sensing and coordinate key aspects of metabolic homeostasis. The EGF family of extracellular ligands has been implicated in the regulation of tissue development and tumorigenesis via the ErbB family of receptor tyrosine kinases [29] [30] [31] . EGF receptor and ErbB2 are uniquely important in engaging a subset of EGFs in cancer cell growth and survival. Interestingly, a distinct subgroup of growth factors called neuregulins (Nrg1-Nrg4) also contain EGF-like domains and primarily signal through ErbB3 and ErbB4 to regulate diverse biological processes 29 . Here we identified Nrg4 as a previously unknown BAT-enriched secreted factor that attenuates hepatic lipogenic signaling and preserves glucose and lipid homeostasis in obesity. Thus, impaired Nrg4 signaling may contribute to the development of type 2 diabetes and NAFLD.
RESULTS

Identification of Nrg4 as a brown fat-enriched secreted protein
To identify BAT-enriched secreted factors, we analyzed the expression profile of the mouse secretome gene set across 12 tissues (GSE10246, Gene Expression Omnibus) and during brown adipocyte differentiation. The secretome database contains a set of 2,169 mouse genes predicted to encode secreted proteins 32 , 1,378 of which have probe sets on Affymetrix mouse genome MOE430 chips. Our analysis identified a cluster of 26 genes whose expression is enriched in mouse brown fat and induced during differentiation of immortalized brown preadipocytes ( Fig. 1a ). Among these, Nrg4 exhibited a highly restricted pattern of expression in adipose tissues. Quantitative PCR (qPCR) analysis indicated that Nrg4 mRNA expression was enriched in BAT and also present at a lower level in white adipose tissue (WAT) (Fig. 1b) . In contrast, its expression in other tissues, including skeletal muscle, liver, brain and heart, was relatively low. Consistent with microarray data, Nrg4 expression was markedly induced during adipocyte differentiation ( Fig. 1c) , reaching a higher level in differentiated immortalized brown adipocytes than in 3T3-L1 white adipocytes and primary hepatocytes ( Fig. 1b) . Nrg4 expression in BAT, but not inguinal and epididymal WAT, was elevated by acute cold exposure, whereas its expression in both BAT and inguinal WAT was augmented by cold acclimation (Fig. 1d) . Nrg4 expression was induced by norepinephrine in differentiated brown adipocytes but not 3T3-L1 adipocytes ( Fig. 1e) .
Nrg4 belongs to a small family of EGF-like (EGFL) domaincontaining proteins that are synthesized as transmembrane precursors and undergo proteolytic cleavage 33 . The released extracellular fragments act on target cells through autocrine, paracrine and endocrine mechanisms. The proteolytic cleavage of Nrg4 near the transmembrane domain is predicted to release a highly conserved N-terminal EGFL peptide ( Supplementary Fig. 1 ) 34, 35 . To map the residues required for Nrg4 cleavage, we generated a panel of alanine mutants (affecting amino acids 51-60) between the EGFL and transmembrane domains. To facilitate detection, full-length wild-type and mutant Nrg4 proteins were fused to the C terminus of secreted alkaline phosphatase (SEAP). Immunoblotting analysis of conditioned medium (CM) from transfected HEK293 cells showed that SEAP-Nrg4 fusion protein was readily detectable in medium ( Fig. 1f) , indicating that the extracellular fragment of Nrg4 undergoes proteolytic cleavage. Compared to wild type controls, mutants with amino acids 53 and 54 (S53A/S54A) or amino acid 53 (S53A) replaced with alanine had markedly lower release of SEAP-Nrg4 fusion proteins into medium, despite having similar expression in total cell lysates. As such, Ser53 appears to be critical for Nrg4 cleavage and release.
Neuregulins transduce signals via activation of the ErbB receptors, particularly ErbB4. To examine whether native Nrg4 can be released into the extracellular space to activate ErbB4, we collected CM from HEK293 cells transiently transfected with a vector expressing fulllength wild-type Nrg4 and used it to treat Min6 cells stably overexpressing ErbB4 (ErbB4-Min6). Compared with CM from control cells, CM from Nrg4-transfected cells elicited strong ErbB4 tyrosine phosphorylation ( Fig. 1g) . Similarly, biologically active Nrg4 could be detected in culture medium from differentiated, immortalized brown adipocytes transduced with Nrg4 retrovirus. Using HEK293 cells with reconstituted expression of ErbB receptor combinations, we found that recombinant Nrg4 augments tyrosine phosphorylation of ErbB3 and ErbB4 but not ErbB2 ( Supplementary Fig. 2a ). While in vivo detection of Nrg4 is desired, an immunological assay with sufficient sensitivity and specificity for the detection of Nrg4 in plasma remains under development.
Nrg4 binding is restricted to the liver A major function of brown fat is nonshivering thermogenesis. We next examined whether Nrg4 is required for defense against excess cold stimulation in Nrg4-null mice generated using a gene trap method. Unexpectedly, despite its abundant expression in BAT, Nrg4 appears to be dispensable for defense against cold exposure-induced hypothermia. Rectal body temperature was nearly indistinguishable between wild-type and Nrg4-knockout mice ( Fig. 2a) . Cold exposure induced expression of Ucp1 and of deiodinase 2 (Dio2), an enzyme involved in thermogenic regulation, to a similar extent in wild-type and knockout mice ( Fig. 2b) . This was also the case with BAT histology, hepatic gene expression, and plasma levels of insulin, adiponectin and leptin ( Fig. 2c and Supplementary Fig. 3 ). These observations raised the possibility that Nrg4 may not directly engage in BAT thermogenesis but may instead act on other tissues after its release from adipose tissues. To identify the target tissue(s) of Nrg4, we generated a fusion protein between SEAP and the extracellular fragment of Nrg4 (SEAP-Nrg4 Ex ) and performed binding assays on frozen tissue sections 36 . The presence of Nrg4 binding sites in tissues can be readily detected by histochemical staining for alkaline phosphatase activity. SEAP-Nrg4 Ex fusion protein was bioactive in receptor binding, as indicated by robust activation of ErbB4 phosphorylation (Fig. 2d) . Although SEAP-Nrg4 Ex binding was near background levels in BAT, heart, skeletal muscle and spleen, we detected strong binding on the liver section as indicated by the presence of SEAP enzymatic staining ( Fig. 2e) . In contrast, Nrg1 exhibited a broader profile of tissue binding ( Supplementary Fig. 2b ). Binding of Nrg4 Ex to hepatocytes was specific as recombinant GST-Nrg4 Ex , but not GST, nearly completely abolished the signal (Fig. 2f) . To determine whether ErbB3 and ErbB4 may mediate Nrg4 binding to hepatocytes, we performed competitive binding assays in the presence of excess amounts of the extracellular fragments of ErbB3 or ErbB4. Extracellular ligand-binding domains of ErbB3 and ErbB4 markedly reduced SEAP-Nrg4 Ex binding on liver sections (Fig. 2g) . These results illustrate that liver is a target tissue of Nrg4, likely through its direct binding to the ErbB receptors.
Nrg4 deficiency exacerbates diet-induced insulin resistance and hepatic steatosis Secreted factors released by adipose tissues exert diverse effects on metabolic homeostasis [21] [22] [23] . To explore the role of Nrg4 in systemic metabolism, we analyzed metabolic parameters of wild-type and Nrg4-deficient mice fed standard chow or high-fat diet (HFD). Nrg4-knockout mice were born at expected Mendelian ratio and gained body weight similarly to controls when fed standard chow ( Fig. 3a) . Upon HFD feeding, Nrg4-null mice gained slightly more weight, accompanied by significantly increased adiposity and reduced percentage of lean body mass. Plasma triacylglyceride (TAG) concentrations were higher in knockout mice than wild-type control mice under ad libitum conditions following HFD feeding (Fig. 3b) . Fasting blood glucose and plasma insulin concentration was higher in HFD-fed Nrg4-deficient mice than wild-type control mice ( Fig. 3c) . Glucose tolerance test and insulin tolerance test revealed that Nrg4 deficiency exacerbated glucose intolerance and insulin resistance after diet-induced obesity ( Fig. 3d) . Although WAT and BAT histology appeared similar, Nrg4-null mouse livers developed more pronounced fat accumulation after HFD feeding, accompanied by increased liver TAG content and plasma alanine aminotransferase (ALT) concentration ( Fig. 3e and Supplementary Fig. 4a ). To assess whether hepatic Nrg4 may be responsible for these metabolic changes, we performed in vivo RNAi knockdown of Nrg4 in HFD-fed mice through tail vein injection of adenoviral vectors. Liver-specific Nrg4 knockdown did not alter the amount of plasma and liver TAG or hepatic gene expression ( Supplementary Fig. 4c,d) .
Because Nrg4 binding was restricted to the liver, we next performed transcriptional profiling on total liver RNA from HFD-fed wild-type and knockout mice to identify metabolic pathways targeted npg by Nrg4. Among the genes altered by Nrg4 deficiency was a cluster involved in lipid metabolism. Notably, hepatic expression of several genes involved in de novo lipogenesis, including those encoding glucose kinase (Gck), malic enzyme (Me1), fatty acid synthase (Fasn), stearoyl-CoA desaturase 1 (Scd1) and ELOVL fatty acid elongase 5 (Elovl5), was significantly higher in Nrg4-deficient mice compared to in wild-type control mice ( Fig. 3f,g) . The expression of Fsp27, a lipid droplet protein associated with hepatic steatosis, and several proinflammatory cytokines was also increased ( Fig. 3g and Supplementary  Fig. 4b ). In contrast, mRNA expression of genes involved in fatty acid β-oxidation (Ehhadh, Acox1 and Cpt1a), gluconeogenesis and mitochondrial oxidative phosphorylation was comparable between the two groups. The mRNA expression of several transcriptional regulators of hepatic metabolism, including Ppargc1a, Ppargc1b, Mlxipl and Srebf2, was also similar between control and knockout livers. In contrast, the amount of Srebp1c mRNA, a key regulator of de novo lipogenesis and triglyceride synthesis 37 , was significantly increased in Nrg4 knockout mouse livers. Importantly, expression of precursor SREBP1 (pSREBP1) and the cleaved, transcriptionally active isoform of SREBP1 in the nucleus (nSREBP1) was also elevated (Fig. 3h) . Activation status of AMPK and AKT, key mediators of nutritional signaling, appeared similar between two groups. From these results, we concluded that Nrg4 deficiency leads to aberrant induction of hepatic lipogenesis and predisposes mice to diet-induced hepatic steatosis.
Nrg4 cell-autonomously attenuates de novo lipogenesis in hepatocytes
To determine whether Nrg4 regulates de novo lipogenesis in a cellautonomous manner, we performed studies in cultured primary mouse hepatocytes. Previous work has demonstrated that liver expresses all ErbB receptors except ErbB2 (ref. 38 ). However, ErbB4 expression in hepatocytes is relatively low in culture. To reconstitute ErbB signaling in hepatocytes, we transduced primary hepatocytes with control (GFP) or ErbB4 adenoviral vectors and examined the effects of Nrg4 on receptor activation and downstream signaling. As expected, ErbB4 expression was below the detectable range in hepatocytes transduced with GFP adenovirus (Fig. 4a) . Adenoviral-mediated expression of ErbB4 resulted in autophosphorylation that was moderately increased by GST-Nrg4 Ex treatments. Of note, GST-Nrg4 Ex treatment elicited a dose-dependent increase of tyrosine phosphorylation of endogenous ErbB3 and signal transducer and activator of transcription 5 (STAT5) proteins without affecting total ErbB3 and STAT5 levels. Because ErbB3 does not have intrinsic kinase activity, increased phosphorylation is likely due to ligand-dependent heterodimerization with ErbB4 in response to Nrg4. Previous studies have demonstrated that ErbB receptor activation stimulates the STAT5 signaling pathway in cultured cells and in vivo 39, 40 . Our results indicate that this signaling pathway is also operational in hepatocytes. Notably, the stimulation of ErbB3 and STAT5 phosphorylation was absent when we used a kinase-dead mutant of ErbB4 (ErbB4 KD) ( Fig. 4b) . Treatments of hepatocytes with JNJ28871063, a pan-ErbB inhibitor, also abolished the response to GST-Nrg4 Ex (Fig. 4c) , suggesting that kinase activity of ErbB4 is required for mediating the stimulation of ErbB3 and STAT5 in response to Nrg4. Hepatic lipogenesis is highly responsive to nutritional and hormonal signals. The induction of lipogenic gene program in the fed state requires transcriptional activation of SREBP1c, which is a direct target of the nuclear hormone receptor liver X receptor (LXR) 41, 42 . We next examined whether ErbB4 activation by Nrg4 directly impacts the SREBP1c-lipogenesis axis in hepatocytes in response to LXR activation. npg Hepatocytes transduced with GFP or ErbB4 adenoviruses were treated with vehicle (DMSO) or T0901317, a potent agonist for LXR, in the presence of GST or GST-Nrg4 Ex . As expected, T0901317 treatment strongly induced mRNA expression of Srebp1c and lipogenic genes, such as Fasn and Scd1, in hepatocytes transduced with GFP ( Fig. 4d) . Treatment of ErbB4-transduced hepatocytes with GST-Nrg4 Ex significantly lowered the stimulatory effects of T0901317 on these genes. The expression of Abca1, another LXR target gene, was also reduced in response to ErbB4-Nrg4 activation. Consistently, incorporation of [ 14 C]acetate into lipids in hepatocytes was significantly inhibited by activation of Nrg4-ErbB signaling (Fig. 4e) .
Using hepatocytes isolated from Erbb3 flox/flox and Erbb3 flox/flox :Alb-Cre mutant mice, we found that the absence of ErbB3 impaired the attenuation of Srebp1c and Fasn expression by Nrg4 (Fig. 4f) . STAT5 has been demonstrated to exert inhibitory effects on nuclear hormone receptor signaling 43 . To examine whether STAT5 activation directly modulates the transcriptional activity of LXR, we performed reporter gene assay using a construct encoding luciferase fused to the LXR responsive element (LXRE). As expected, cotransfection of LXR and RXR increased the LXRE reporter luciferase activity in Hepa1 hepatoma cells (Fig. 4g) . Co-transfection of constitutively active STAT5 significantly inhibited the increase of LXRE reporter gene expression, suggesting that STAT5 activation may transrepress LXR and attenuate its transcriptional activity.
Adipose tissue Nrg4 expression is reduced in mouse and human obesity
We next examined whether adipose Nrg4 expression is altered in mouse and human obesity. Compared to that in lean controls, expression of Nrg4 mRNA in epididymal WAT was markedly lower in mice with high-fat diet (HFD)-induced obesity or genetic obesity caused by leptin (ob/ob) or leptin receptor (db/db) deficiency (Fig. 5a) .
Although Nrg4 mRNA expression in brown fat was similar between lean and HFD-induced obese mice, it was significantly lower in BAT from ob/ob and db/db mice, which are more severe models of obesity. Fractionation studies indicated that Nrg4 mRNA expression was detected nearly exclusively in adipocytes, but not in the stromal vascular fraction, and was significantly lower in the obese group than in lean controls (Fig. 5b) . We included adiponectin and nitric oxide synthase 2 as controls for adipocytes and stromal vascular cells, respectively. Adipose tissue inflammation impairs insulin sensitivity and metabolic homeostasis in part through augmented proinflammatory cytokine signaling [44] [45] [46] of Nrg4 in adipocytes, we treated differentiated brown adipocytes and 3T3-L1 adipocytes with TNF-α, a prototypical obesity-induced cytokine 47 . We found that Nrg4 mRNA expression was decreased by TNF-α treatments in both brown and white adipocytes (Fig. 5c) . We observed similar inhibition of Nrg4 expression after interleukin-1β (IL-1β) treatments. Thus, the reduction of adipocyte Nrg4 expression is likely a consequence of augmented proinflammatory cytokine signaling in obesity.
To investigate whether Nrg4 expression is also reduced in human obesity, we examined its mRNA levels in subcutaneous WAT (scWAT) from a cohort of individuals with a wide range of body fat mass and found that scWAT NRG4 mRNA levels inversely correlated with log percentage of body fat mass and log liver fat content (Fig. 5d) . When assessing NRG4 expression in body mass index-matched individuals, we found that NRG4 mRNA levels in both subcutaneous and visceral adipose tissues were significantly lower in individuals with impaired npg glucose tolerance or type 2 diabetes than in those with normal glucose tolerance (Fig. 5e) . Together with the observations that Nrg4deficient mice developed more severe diet-induced hepatic steatosis, our results strongly suggest that inadequate Nrg4 expression may be causally linked to the pathogenesis of NAFLD.
Transgenic expression of Nrg4 improves diet-induced metabolic disorders
A key prediction from these observations is that elevating Nrg4 expression will protect mice from obesity-associated metabolic disorders. To test this, we generated Nrg4 transgenic mice using a P2 promoter-enhancer and chose line 111, which exhibited adiposeselective overexpression for metabolic studies. Nrg4 transgenic mice were indistinguishable from wild-type littermates when fed standard chow. Further, body temperature, BAT gene expression and plasma parameters were similar between control and transgenic mice before and after cold exposure (Supplementary Fig. 5c ). Upon HFD feeding, transgenic mice gained slightly but still significantly less body weight and adiposity than controls (P < 0.05, Supplementary Fig. 6a,b) .
Histological analyses and measurements of liver lipid content indicated that transgenic mice had significantly reduced hepatic steatosis ( Fig. 6a,b) . Plasma TAG levels were also lower in the transgenic group (Fig. 6b) . Fatty acid profile analysis of liver TAG demonstrated that transgenic mice have lower levels of major fatty acid species, including palmitic acid (C16:0), oleic acid (C18:1) and linolenic acid (C18:2), than wild-type control mice (Supplementary Fig. 6c) . Notably, the desaturation index (C18:1n9/C18:0), which reflects cellular SCD1 activity, was significantly lower in the transgenic group (Fig. 6c) . Nrg4 transgenic mice had lower blood glucose and insulin concentrations ( Fig. 6d) and improved glucose tolerance and insulin sensitivity (Fig. 6e) . Accordingly, we found that expression of SREBP1c mRNA and protein was significantly lower in transgenic mouse livers ( Fig. 6f,g) . Expression of lipogenic genes, including Gck, Acl, Acc1, Me1, Fasn and Scd1, and genes encoding proinflammatory cytokines, including Tnf, Il1b and Ccl2 (Supplementary Fig. 6d) , was lower in the transgenic mouse livers. Plasma ALT levels also trended lower in this group ( Supplementary  Fig. 6e ). These results demonstrate that transgenic expression of Nrg4 in adipose tissues is sufficient to attenuate hepatic lipogenesis and ameliorate diet-induced fatty liver disease and insulin resistance.
DISCUSSION
Brown and beige adipocytes are capable of activating uncoupled respiration through UCP1-mediated proton leak and heat generation. This intrinsic thermogenic function is critical for the defense against excess cold exposure and contributes to whole-body energy balance. However, whether brown fat engages other metabolic tissues via its release of endocrine factors remains poorly understood. Here we define a previously unknown mechanism through which brown adipocytes may regulate systemic metabolism independent of UCP1mediated thermogenesis. Although Nrg4 expression is enriched in BAT, both brown and white adipocytes likely contribute to the release of Nrg4 into circulation (Fig. 6h) . The significance of white fat as a source of Nrg4 may be even more relevant in some humans given the paucity of brown and beige fats in adults. Notably, transgenic rescue of Nrg4 expression in adipose tissues is sufficient to ameliorate the severity of fatty liver and insulin resistance, raising the prospect of developing Nrg4 as an effective therapeutic biologic for the treatment of NAFLD and type 2 diabetes. Excessive stimulation of SREBP1-mediated lipogenesis has been observed in mouse models of fatty liver disease as well as in human NAFLD 37, 48, 49 . Of note, liver-specific transgenic expression of the transcriptionally active form of SREBP1c increases hepatic lipogenesis, leading to excess adiposity, hepatic steatosis and hypertriglyceridemia 37, 50, 51 , whereas inhibition of the SREBP pathway has the opposite effects on hepatic fat accumulation and whole-body energy metabolism 52, 53 . Several lines of evidence support the notion that Nrg4 directly acts on the liver and regulates hepatic lipogenesis. First, the extracellular EGF-like domain of Nrg4 exhibited strong binding to hepatocytes when fused to SEAP. Nrg4 binding in the liver was nearly completely abolished when excess GST-Nrg4 Ex or CM containing the extracellular domains of ErbB3 and ErbB4 were included as competitors in the binding assays. As such, Nrg4 likely directly binds to ErbB3 and/or ErbB4 on hepatocyte cell surface. Using cultured hepatocytes with reconstituted ErbB4 expression, we found that Nrg4 could trigger dose-dependent activation of endogenous ErbB3 and downstream signaling pathway, most notably transcription factor STAT5. ErbB3 does not have an active kinase domain but can heterodimerize with ErbB4 in response to ligand binding, resulting in receptor phosphorylation and the activation of downstream effectors. Given that hepatocytes express very low levels of ErbB2 (ref. 38) , and that EGFR does not bind to Nrg4 (ref. 35) , our data are consistent with ErbB3 and ErbB4 serving as major Nrg4 receptors in the liver. Finally, the activation of Nrg4 signaling in hepatocytes resulted in cell-autonomous inhibition of the SREBP1c-lipogenic pathway through transrepression of LXR by STAT5. Although the liver appeared to be a major target tissue of Nrg4, it cannot be ruled out that Nrg4 actions in other tissues, including the central nervous system, may contribute to its regulation of systemic metabolism.
Nrg4 mRNA expression is enriched in, but not exclusively restricted to, brown fat. Similar to our work, a recent study identified Nrg4 as a transcript exhibiting strong enrichment in brown adipocytes 54 . The levels of Nrg4 mRNA are significantly reduced in adipose tissues in mouse and human obesity. Our studies demonstrate that Nrg4 undergoes proteolytic cleavage to release the biologically active extracellular ligand. However, owing to a lack of robust immunological assays, important questions regarding Nrg4 levels in circulation and its nutritional regulation remain to be addressed. Despite this, our in vivo gain-and loss-of-function studies illustrate the importance of the Nrg4-ErbB signaling pathway in balancing hepatic lipogenesis in obesity. No specific and effective therapies are currently available to treat NAFLD. Future studies are needed to explore the potential of Nrg4 as a therapeutic biologic for treating obesity-associated disorders, such as NAFLD and type 2 diabetes.
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